Elutia Inc. Files 8-K, Formerly Aziyo Biologics

TL;DR

Elutia Inc. (formerly Aziyo Biologics) filed an 8-K on Feb 3, 2025, confirming its name and Delaware incorporation.

AI Summary

On February 3, 2025, Elutia Inc. (formerly Aziyo Biologics, Inc.) filed an 8-K report. The filing indicates a change in the company's name and jurisdiction of incorporation from Delaware to Delaware, with no change in the former name or date of name change. The company's principal executive offices are located at 12510 Prosperity Drive, Suite 370, Silver Spring, MD 20904.

Why It Matters

This filing formally announces a corporate name change, which can signal strategic shifts or rebranding efforts for investors to monitor.

Risk Assessment

Risk Level: low — The filing is primarily administrative, confirming a name change and corporate details without disclosing significant financial or operational events.

Key Players & Entities

• Elutia Inc. (company) — Registrant
• Aziyo Biologics, Inc. (company) — Former company name
• February 3, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• 12510 Prosperity Drive, Suite 370, Silver Spring, MD 20904 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — hich registered Class A Common Stock, $0.001 par value per share ELUT The Nasdaq

Filing Documents

• tm254968d1_8k.htm (8-K) — 50KB
• 0001104659-25-008297.txt ( ) — 225KB
• elut-20250203.xsd (EX-101.SCH) — 3KB
• elut-20250203_lab.xml (EX-101.LAB) — 33KB
• elut-20250203_pre.xml (EX-101.PRE) — 22KB
• tm254968d1_8k_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. The information set forth under Item 8.01 below is incorporated by reference into this Item 2.02.

01 Other Events

Item 8.01 Other Events. Elutia Inc. ("we," "us," "our," the "Company" and "Elutia") is in the process of finalizing its results for the year ended December 31, 2024. The Company estimates its net sales for the year ended December 31, 2024 to be as follows (in thousands, except percentages): Year Ended December 31, Preliminary 2024 2023 Change Amount % of Net Sales Amount % of Net Sales $ % Products : Device protection $ 9,905 41 % $ 9,401 38 % $ 504 5 % Women's health 11,554 47 % 10,304 42 % 1,250 12 % Cardiovascular 2,916 12 % 5,040 20 % (2,124 ) (42 )% Total Net Sales $ 24,375 $ 24,745 $ (370 ) (1 )% The Company's preliminary net sales estimates for the year ended December 31, 2024 are based on currently available information and do not present all necessary information for an understanding of the Company's financial condition as of December 31, 2024 or the Company's results of operations for the year ended December 31, 2024. The Company's final net sales upon completion of its closing procedures may vary from the preliminary estimates as a result of the completion of final adjustments, and other developments arising between now and the time that its net sales results for such period are finalized. Complete results as of, and for the year ended, December 31, 2024, including net sales, will be included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024. See "Forward-Looking Statements" below and the information under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 23, 2023, as updated by the Company's subsequent Quarterly Reports on Form 10-Q, for additional information regarding factors that could result in differences between these preliminary and the actual net sales results we will report for the year ended December 31, 2024. The Company's independent registered public accounting firm, PricewaterhouseCoopers LLP, has not audited, revie

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential," "promise" or similar references to future periods. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including any statements and information regarding the Company's preliminary net sales estimates. These forward-looking statements are based on our management's beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in the forward-looking statements, including, but not limited to the following: our ability to successfully commercialize, market and sell our newly approved EluPro product; our ability to continue as a going concern; our ability to achieve or sustain profitability; the risk of product liability claims and our ability to obtain or maintain adequate product liability insurance; our ability to defend against the various lawsuits and claims related to our recalled FiberCel and other viable bone matrix products and avoid a material adverse financial consequence from those lawsuits and claims; the continued and future acceptance of our products by the medical community; our ability to enhance our products, expand our product indications and develop, acquire and commercialize additional product offerings; our de

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ELUTIA INC. Date: February 3, 2025 By: /s/ Matthew Ferguson Matthew Ferguson Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR